Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

http://www.wikidata.org/entity/Q34351993

about

Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin

P2860

Q30661709-865CF7C8-0918-4DAC-9654-BAB66CA25EA5 Q33559031-9C5182C7-CDA7-4F10-9D24-BC7652B21275 Q36675928-9F2C8720-6B96-4535-B324-AE7414826A37 Q37235279-D264948C-26F4-405A-BB10-B71385E6788A

P2860

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

http://www.wikidata.org/entity/Q34351993

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@ast

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@en

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@nl

type

label

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@ast

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@en

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@nl

prefLabel

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@ast

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@en

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@nl

P1433

Q34351993-6FB41B91-CEAF-4FF5-8F14-DBDBD1217662

P1476

Q34351993-46C278BD-7A8C-4E7E-8BAE-BE9B80531E10

P2093

Q34351993-039DC092-DA31-4EE1-8A06-7611137D94BD

Q34351993-17754FA2-1557-45F6-A3A7-E1ADA74701FB

Q34351993-27BE892A-98D1-432E-AA7A-53B43227EA63

Q34351993-37153C9E-B92E-441F-B962-FAC78129E0D0

Q34351993-3F292320-3BAA-4472-A2C5-3FF13170B95B

Q34351993-543E8E08-DD2F-44BF-9594-FAD8239BEC6D

Q34351993-7FFA48A5-4B6C-4127-BF68-D96517586CCE

Q34351993-8F2FD8AB-FF04-4A0A-9554-4B8A00B55C27

Q34351993-95BBD000-1803-446F-B60C-B1562986F41D

Q34351993-AABE2054-739C-4830-A90F-1F81A2D46839

P2860

Q34351993-39EFBFCD-8627-4AF0-B966-5B6BBF9F1FE2

Q34351993-42AF14BD-3BFE-46A2-B527-7D87F8E5FAAD

Q34351993-6A265C3C-65D5-4CBE-912B-231DD1F2876F

Q34351993-6B7C0295-3DAA-4899-96DE-B4DD34A27CEF

Q34351993-6C06C806-492D-481D-8E05-99B30350F88D

Q34351993-7F3ACE13-6C48-429F-95E7-AA800F343FEA

Q34351993-83A79EF2-1A4F-4C02-A45C-FB4E653AF5A7

Q34351993-925DC620-7792-473C-BDBF-007A112D8E83

Q34351993-AA774A59-405C-4D72-93E9-5BB477EF0CDA

Q34351993-AAA873E2-76AD-420C-B8B9-DD16C565EFDA

P304

Q34351993-FA91E4CD-6B87-4219-9D85-B191C113786B

P31

Q34351993-A77F2571-5BED-47C1-B23B-6C61A989D23C

P356

Q34351993-CD600071-3DB2-488A-80E5-09A2242172E4

P407

Q34351993-AE8A6959-4B8B-4C37-A170-57A0B72A0004

P433

Q34351993-913CD085-07AD-4C11-AB24-6211B584B3BB

P478

Q34351993-DC1B63A4-EC8E-4FB7-B21B-3E29FD78562C

P50

Q34351993-43D53358-5058-44D4-8105-9DD02F06F868

Q34351993-459EBAA0-39E6-44CA-9A27-0EBA55978631

P577

Q34351993-5D6BDF45-5275-473C-A86F-A05ADB21C9D3

P698

Q34351993-A8A79ADA-AFDE-45DE-993F-178A0C19A1C7

P932

Q34351993-5B4216B7-AC17-443F-B85F-41B9634386B9

P356

AAC.50.2.667-673.2006

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

@en

P2093

Andreas Plettenberg

http://www.w3.org/2001/XMLSchema#string

Antje Breske

http://www.w3.org/2001/XMLSchema#string

Charlotte Kloft

http://www.w3.org/2001/XMLSchema#string

Christian Herzmann

http://www.w3.org/2001/XMLSchema#string

Christiane Moecklinghoff

http://www.w3.org/2001/XMLSchema#string

Christoph Weber

http://www.w3.org/2001/XMLSchema#string

Frank Goebel

http://www.w3.org/2001/XMLSchema#string

Guido Kruse

http://www.w3.org/2001/XMLSchema#string

Hartmut Stocker

http://www.w3.org/2001/XMLSchema#string

Hubert Schulbin

http://www.w3.org/2001/XMLSchema#string

P2860

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

Pathophysiology of body composition and metabolic abnormalities in HIV-infection: therapeutic implications.

Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting.

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

P304

667-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.50.2.667-673.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Schlomo Staszewski

Keikawus Arastéh

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16436725

http://www.w3.org/2001/XMLSchema#string

P932

1366872

http://www.w3.org/2001/XMLSchema#string